Loading clinical trials...
Loading clinical trials...
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previou...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06563895 · Amyloidosis, Amyloid Cardiomyopathy, and more
NCT07266116 · Systemic Light Chain Amyloidosis
NCT07030517 · Multiple Myeloma
North Carolina Cancer Hospital
Chapel Hill, North Carolina
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions